Abstract
A significant proportion of patients with type 1 and 2 diabetes treated with insulin is still not well controlled. This may be due to the risk of indequate insulin therapy (currently hypoglycemia and postprandial hyperglycemia).
To improve insulin regimes, new types of insulin have been developed to allow to get still closer to sustained normoglycemia than the currently used insulin analogues (glargine, detemir, aspart, glulisine, lispro). Degludec (very long acting with a flat pharmacokinetic profile) and FiAsp (very fast onset of action) are currently used in real-life practice.